Age (years)
|
median (range)
|
66 (51-87)
|
---|
Histology
|
Ductal/other
|
48/9
|
Estrogen receptor
|
RE+/RE-
|
52/5
|
Progesteron receptor
|
RP+/RP-
|
45/12
|
Tumor stage
|
Tis/T1/T2
|
1/48/8
|
Nodal stage
|
N0/N1
|
54/3
|
Chemotherapy
|
yes/no
|
15/42
|
|
CMF
|
5
|
|
FEC
|
5
|
|
EC
|
1
|
|
EC+ Docetaxel
|
4
|
Hormone-therapy
|
yes/no
|
52/5
|
-
Abbreviations: CMF: Cyclophosphamide (600 mg/m2, Methotrexate 40 mg/m2, 5-FU 600 mg/m2 d 1 and d 8 q 4 weeks × 6); FEC (5-FU 600 mg/m2, Epirubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 d 1 q 3 weeks × 6); EC (Epirubicin 60 mg/m2, Cyclophosphamide 600 mg/m2 d1 q 3 weeks × 4); EC+ Docetaxel : EC followed by Docetaxel (100 mg/m2 d1 q 3 weeks × 4)